Corticolimbic circuitry as a druggable target in schizophrenia spectrum disorders: a narrative review
Abstract Schizophrenia spectrum disorders (SSD) involve disturbances in the integration of perception, emotion and cognition. The corticolimbic system is an interacting set of cortical and subcortical brain regions critically involved in this process. Understanding how neural circuitry and molecular...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2025-01-01
|
| Series: | Translational Psychiatry |
| Online Access: | https://doi.org/10.1038/s41398-024-03221-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585353087680512 |
|---|---|
| author | Abigail Gee Paola Dazzan Anthony A. Grace Gemma Modinos |
| author_facet | Abigail Gee Paola Dazzan Anthony A. Grace Gemma Modinos |
| author_sort | Abigail Gee |
| collection | DOAJ |
| description | Abstract Schizophrenia spectrum disorders (SSD) involve disturbances in the integration of perception, emotion and cognition. The corticolimbic system is an interacting set of cortical and subcortical brain regions critically involved in this process. Understanding how neural circuitry and molecular mechanisms within this corticolimbic system may contribute to the development of not only positive symptoms but also negative and cognitive deficits in SSD has been a recent focus of intense research, as the latter are not adequately treated by current antipsychotic medications and are more strongly associated with poorer functioning and long-term outcomes. This review synthesises recent developments examining corticolimbic dysfunction in the pathophysiology of SSD, with a focus on neuroimaging advances and related novel methodologies that enable the integration of data across different scales. We then integrate how these findings may inform the identification of novel therapeutic and preventive targets for SSD symptomatology. A range of pharmacological interventions have shown initial promise in correcting corticolimbic dysfunction and improving negative, cognitive and treatment-resistant symptoms. We discuss current challenges and opportunities for improving the still limited translation of these research findings into clinical practice. We argue how our knowledge of the role of corticolimbic dysfunction can be improved by combining multiple research modalities to examine hypotheses across different spatial and temporal scales, combining neuroimaging with experimental interventions and utilising large-scale consortia to advance biomarker identification. Translation of these findings into clinical practice will be aided by consideration of optimal intervention timings, biomarker-led patient stratification, and the development of more selective medications. |
| format | Article |
| id | doaj-art-593996e59e5b412a9b2e1adb510b26fd |
| institution | Kabale University |
| issn | 2158-3188 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Translational Psychiatry |
| spelling | doaj-art-593996e59e5b412a9b2e1adb510b26fd2025-01-26T12:53:42ZengNature Publishing GroupTranslational Psychiatry2158-31882025-01-0115111510.1038/s41398-024-03221-2Corticolimbic circuitry as a druggable target in schizophrenia spectrum disorders: a narrative reviewAbigail Gee0Paola Dazzan1Anthony A. Grace2Gemma Modinos3Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College LondonDepartment of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College LondonDepartments of Neuroscience, Psychiatry and Psychology, University of PittsburghDepartment of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College LondonAbstract Schizophrenia spectrum disorders (SSD) involve disturbances in the integration of perception, emotion and cognition. The corticolimbic system is an interacting set of cortical and subcortical brain regions critically involved in this process. Understanding how neural circuitry and molecular mechanisms within this corticolimbic system may contribute to the development of not only positive symptoms but also negative and cognitive deficits in SSD has been a recent focus of intense research, as the latter are not adequately treated by current antipsychotic medications and are more strongly associated with poorer functioning and long-term outcomes. This review synthesises recent developments examining corticolimbic dysfunction in the pathophysiology of SSD, with a focus on neuroimaging advances and related novel methodologies that enable the integration of data across different scales. We then integrate how these findings may inform the identification of novel therapeutic and preventive targets for SSD symptomatology. A range of pharmacological interventions have shown initial promise in correcting corticolimbic dysfunction and improving negative, cognitive and treatment-resistant symptoms. We discuss current challenges and opportunities for improving the still limited translation of these research findings into clinical practice. We argue how our knowledge of the role of corticolimbic dysfunction can be improved by combining multiple research modalities to examine hypotheses across different spatial and temporal scales, combining neuroimaging with experimental interventions and utilising large-scale consortia to advance biomarker identification. Translation of these findings into clinical practice will be aided by consideration of optimal intervention timings, biomarker-led patient stratification, and the development of more selective medications.https://doi.org/10.1038/s41398-024-03221-2 |
| spellingShingle | Abigail Gee Paola Dazzan Anthony A. Grace Gemma Modinos Corticolimbic circuitry as a druggable target in schizophrenia spectrum disorders: a narrative review Translational Psychiatry |
| title | Corticolimbic circuitry as a druggable target in schizophrenia spectrum disorders: a narrative review |
| title_full | Corticolimbic circuitry as a druggable target in schizophrenia spectrum disorders: a narrative review |
| title_fullStr | Corticolimbic circuitry as a druggable target in schizophrenia spectrum disorders: a narrative review |
| title_full_unstemmed | Corticolimbic circuitry as a druggable target in schizophrenia spectrum disorders: a narrative review |
| title_short | Corticolimbic circuitry as a druggable target in schizophrenia spectrum disorders: a narrative review |
| title_sort | corticolimbic circuitry as a druggable target in schizophrenia spectrum disorders a narrative review |
| url | https://doi.org/10.1038/s41398-024-03221-2 |
| work_keys_str_mv | AT abigailgee corticolimbiccircuitryasadruggabletargetinschizophreniaspectrumdisordersanarrativereview AT paoladazzan corticolimbiccircuitryasadruggabletargetinschizophreniaspectrumdisordersanarrativereview AT anthonyagrace corticolimbiccircuitryasadruggabletargetinschizophreniaspectrumdisordersanarrativereview AT gemmamodinos corticolimbiccircuitryasadruggabletargetinschizophreniaspectrumdisordersanarrativereview |